Ibrance is a prescription drug approved by the Food and Drug Administration (FDA) to treat metastatic breast cancer in combination with Femara. Ibrance is prescribed in cases where women are postmenopausal and tumors are estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Ibrance is also referred to by its drug name, Palbociclib.
Ibrance is a member of a class of drugs called kinase inhibitors, and it is designed to inhibit the growth of cells. Ibrance is believed to work by slowing the growth of tumors.
How do I take it?
Prescribing information states that Ibrance is taken once daily with meals.
Ibrance comes in capsule form.
The FDA-approved label for Ibrance lists common side effects including decrease in the number of white blood cells, fatigue, weakness, anemia, nausea, cold-like symptoms, hair loss, vomiting, diarrhea, numbness or tingling in extremities, loss of appetite, mouth sores, and nosebleeds.
Rare but serious side effects listed for Ibrance include severe infections and pulmonary embolisms (blood clots in the lungs).